Deutsch English Français

Contact

EP1701736

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1701736

EP1701736 - Flt-3L for use in the prevention of diabetes [Right-click to bookmark this link]
Former [2006/38]	THERAPEUTIC AGENTS AND USES THEREFOR
	[2010/13]
Status	The application is deemed to be withdrawn Status updated on 01.04.2011 Database last updated on 24.04.2024
Most recent event Tooltip	01.04.2011	Application deemed to be withdrawn	published on 04.05.2011 [2011/18]
Applicant(s)	For all designated states THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH 1G Royal Parade Parkville, VIC 3052 / AU
	[2006/38]
Inventor(s)	01 / SHORTMAN, Ken 92 Wilson Street Carlton North, Victoria 3054 / AU
	02 / O'KEEFFE, Meredith 10 Hudson Grove West Brunswick, Victoria 3055 / AU
	03 / FANCKE, Ben 4 Kelvin Grove Ashburton, Victoria 3147 / AU
	04 / HARRISON, Len 27 Park Street St Kilda West, Victoria 3182 / AU
	05 / STEPTOE, Ray 16 Glenlyon Drive Ashgrove, Queensland 4060 / AU
	06 / VREMEC, David 2 Brett Place Ferntree Gully, Victoria 3156 / AU
	[2006/38]
Representative(s)	Jones, Elizabeth Louise Dehns St Bride's House 10 Salisbury Square London EC4Y 8JD / GB
	[N/P]
Former [2006/38]	Jones, Elizabeth Louise Frank B. Dehn & Co. St Bride's House 10 Salisbury Square London EC4Y 8JD / GB
Application number, filing date	04802141.4	23.12.2004
	[2006/38]
	WO2004AU01840
Priority number, date	AU20030907195	24.12.2003 Original published format: AU 2003907195
	[2006/38]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2005060992
	Date:	07.07.2005
	Language:	EN
	[2005/27]
	Type:	A1 Application with search report
	No.:	EP1701736
	Date:	20.09.2006
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 07.07.2005 takes the place of the publication of the European patent application.
	[2006/38]
Search report(s)	International search report - published on:	AU	07.07.2005
	(Supplementary) European search report - dispatched on:	EP	09.04.2008
Classification	IPC:	A61K38/17, A61P3/10	[2010/19]
	CPC:	A61K38/17 (EP,US); A61P1/04 (EP); A61P1/18 (EP); A61P13/12 (EP); A61P17/00 (EP); A61P17/06 (EP); (+) A61P19/02 (EP); A61P21/00 (EP); A61P25/00 (EP); A61P27/02 (EP); A61P29/00 (EP); A61P3/10 (EP); A61P31/12 (EP); A61P35/00 (EP); A61P37/02 (EP); A61P37/04 (EP); A61P37/08 (EP) (-)
	Former IPC [2010/13]	A61P3/10
	Former IPC [2006/38]	A61K38/45, A61K38/19, A61P35/00, A61P37/02
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/38]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	YU	Not yet paid
Title	German:	Flt-3L zur Vorbeugung von Diabetes	[2010/30]
	English:	Flt-3L for use in the prevention of diabetes	[2010/13]
	French:	Flt-3L pour la prévention du diabète	[2010/30]
	Former [2006/38]	THERAPEUTISCHE MITTEL UND IHRE VERWENDUNGEN
	Former [2006/38]	THERAPEUTIC AGENTS AND USES THEREFOR
	Former [2006/38]	AGENTS THERAPEUTIQUES ET UTILISATIONS
Entry into regional phase	17.07.2006	National basic fee paid
	17.07.2006	Search fee paid
	17.07.2006	Designation fee(s) paid
	17.07.2006	Examination fee paid
Examination procedure	24.10.2005	Request for preliminary examination filed International Preliminary Examining Authority: AU
	17.07.2006	Examination requested [2006/38]
	04.07.2008	Despatch of a communication from the examining division (Time limit: M06)
	13.01.2009	Reply to a communication from the examining division
	18.03.2009	Despatch of a communication from the examining division (Time limit: M06)
	14.09.2009	Reply to a communication from the examining division
	05.07.2010	Communication of intention to grant the patent
	16.11.2010	Application deemed to be withdrawn, date of legal effect [2011/18]
	20.12.2010	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2011/18]
Fees paid	Renewal fee
	17.07.2006	Renewal fee patent year 03
	12.12.2007	Renewal fee patent year 04
	15.12.2008	Renewal fee patent year 05
	11.12.2009	Renewal fee patent year 06
	Penalty fee
	Additional fee for renewal fee
	31.12.2010	07 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]US5554512 (LYMAN STEWART D [US], et al) [Y] 3,5,6,27 * claims 1-21 * * column 3, line 25 - line 31 * * column 3, line 32 - line 39 * * column 4, line 33 - line 39 *;
		[YX]WO02080952 (LORANTIS LTD [GB], et al) [YX] 1,2,11-14,22-26 * claims 1,19 * * page 86, line 9 - line 13 * * claims 22-25 * * page 86, line 9 - page 93, line 3 *;
		[Y]WO03078573 (UNIV YALE [US], et al) [Y] 4-6,15 * page 7, line 8 - line 22 *;
		[Y]JP2003277289 (TAKEDA CHEMICAL INDUSTRIES LTD) [Y] 4-6,15 * claim 10 *;
		[Y]WO03089602 (UNIV YALE [US], et al) [Y] 4-6,15 * claims 1-24 *;
		[Y] - CLARE-SALZLER, M.J. ET AL, "Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer", J.CLINICAL INVESTIGATIONS, (1992), vol. 90, pages 741 - 748, XP002473948 [Y] 1-6,11-15,22-27 * page 747, paragraph 5 - page 748, paragraph 1 * DOI: http://dx.doi.org/10.1172/JCI115946
	International search	[A]WO02067760 (BAYLOR RES INST [US]);
		[A]WO02100317 (UNIV PENNSYLVANIA [US], et al);
		[X]US2003113341 (LYNCH DAVID H [US], et al);
		[X] - MALISZEWSKI C., "Dendritic cells in models of tumor immunity. Role of Flt3 ligand", PATHOL. BIOL., (2001), vol. 49, pages 481 - 483, XP002988636 DOI: http://dx.doi.org/10.1016/S0369-8114(01)00172-9
		[X] - MOREL P. ET AL, "Immunobiology of DC in NOD mice", J. LEUK. BIOL., (1999), vol. 66, pages 276 - 280, XP008049898
		[X] - MCNEEL D.G. ET AL, "Pilot Study of an HLA-A2 Peptide Vaccine Using Flt3 Ligand as a Systemic Vaccine Adjuvant", J. CLIN. IMMUNOL., (2003), vol. 23, no. 1, pages 62 - 72, XP002988637 DOI: http://dx.doi.org/10.1023/A:1021904432489
		[X] - DONG J. ET AL, "Flt-3 Ligand A Potent Dendritic Cell Stimulator and Novel Antitumor AGENT", CANCER BIOLOGY & THERAPY, (2002), vol. 1, no. 5, pages 486 - 488, XP008049899
		[X] - RINI B. I. ET AL, "Flt-3 Ligand and Sequential FL/Interleukin-2 in Patients With Metastatic Renal Carcinoma: Clinical and Biologic Activity", JOURNAL OF IMMUNOTHERAPY, (2002), vol. 25, no. 3, pages 269 - 277, XP008049904 DOI: http://dx.doi.org/10.1097/00002371-200205000-00010
	by applicant	WO9007936
		EP0425731
		WO9219195
		WO9501203
		WO9505452
		WO9602286
		WO9602646
		WO9611698
		WO9640959
		WO9712635
		WO02080952
		- DONG J. ET AL., CANCER BIOLOGY & THERAPY, (2002), vol. 1, no. 5, pages 486 - 488
		- O'KEEFFE ET AL., J EXP MED, (2002), vol. 196, pages 1307 - 1319
		- ALTSCHUL ET AL., NUCL. ACIDS RES., (1997), vol. 25, page 3389
		- AUSUBEL ET AL., Current Protocols in Molecular Biology, JOHN WILEY & SONS INC, pages 1994 - 1998
		- CLARE-SALZLER ET AL., J. CLINICAL INVESTIGATIONS, (1992), vol. 90, pages 741 - 748
		- WELLS, METHODS ENZYMOL., (1991), vol. 202, pages 2699 - 2705
		- MARMUR; DOTY, J. MOL. BIOL., (1962), vol. 5, page 109
		- BONNER; LASKEY, EUR. J. BIOCHEM., (1974), vol. 46, page 83

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p